Silexion Therapeutics Corp (SLXN)
NASDAQ: SLXN · Real-Time Price · USD
7.40
+0.15 (2.07%)
At close: Aug 13, 2025, 4:00 PM
7.54
+0.14 (1.89%)
Pre-market: Aug 14, 2025, 8:51 AM EDT
Silexion Therapeutics Employees
As of December 31, 2024, Silexion Therapeutics had 14 total employees, including 11 full-time and 3 part-time employees.
Employees
14
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,174,500
Market Cap
4.15M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SLXN News
- 2 days ago - Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 13 days ago - Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds - GlobeNewsWire
- 13 days ago - Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation - GlobeNewsWire
- 4 weeks ago - Silexion Therapeutics Announces 1-for-15 Reverse Share Split - GlobeNewsWire
- 5 weeks ago - Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines - GlobeNewsWire
- 2 months ago - PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment - GlobeNewsWire
- 3 months ago - Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer - GlobeNewsWire
- 3 months ago - Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire